$VOR
Vor Biopharma Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023060200 Filed on November 07, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.227M $7.710M
YoY Change -5.69% 6.7%
% of Gross Profit
Research & Development $20.90M $27.61M
YoY Change 22.48% 63.59%
% of Gross Profit
Depreciation & Amortization $892.0K $900.0K
YoY Change 41.14% 0.0%
% of Gross Profit
Operating Expenses $28.12M $35.32M
YoY Change 13.75% 46.53%
Operating Profit -$35.32M
YoY Change 46.53%
Interest Expense $1.863M $2.130M
YoY Change 128.59% 580.51%
% of Operating Profit
Other Income/Expense, Net $2.126M
YoY Change 579.23%
Pretax Income -$26.26M -$33.19M
YoY Change 9.83% 39.52%
Income Tax
% Of Pretax Income
Net Earnings -$26.26M -$33.19M
YoY Change 9.83% 39.52%
Net Earnings / Revenue
Basic Earnings Per Share -$0.49
Diluted Earnings Per Share -$0.39 -$0.49
COMMON SHARES
Basic Shares Outstanding 67.81M 67.54M
Diluted Shares Outstanding 67.61M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $137.2M $160.1M
YoY Change -40.42% 17.66%
Cash & Equivalents $31.36M $45.03M
Short-Term Investments $105.8M $115.1M
Other Short-Term Assets $475.0K $667.0K
YoY Change -79.67% -62.34%
Inventory
Prepaid Expenses $3.153M $3.673M
Receivables
Other Receivables
Total Short-Term Assets $140.8M $164.4M
YoY Change -40.58% 15.21%
LONG-TERM ASSETS
Property, Plant & Equipment $10.05M $10.82M
YoY Change -20.45% -16.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.812M $4.086M
YoY Change 64.51% 41.97%
Total Long-Term Assets $57.32M $58.59M
YoY Change -8.16% -7.95%
TOTAL ASSETS
Total Short-Term Assets $140.8M $164.4M
Total Long-Term Assets $57.32M $58.59M
Total Assets $198.1M $223.0M
YoY Change -33.82% 8.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $815.0K $1.309M
YoY Change -54.01% 58.86%
Accrued Expenses $10.88M $10.27M
YoY Change 37.88% 63.39%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $15.57M $15.39M
YoY Change 18.7% 38.61%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $31.83M $32.90M
YoY Change -10.69% -9.95%
Total Long-Term Liabilities $31.83M $32.90M
YoY Change -10.69% -9.95%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.57M $15.39M
Total Long-Term Liabilities $31.83M $32.90M
Total Liabilities $47.40M $48.24M
YoY Change -2.78% 1.27%
SHAREHOLDERS EQUITY
Retained Earnings -$340.1M -$313.8M
YoY Change 53.04% 58.25%
Common Stock $490.9M $488.9M
YoY Change 3.65% 36.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $150.7M $174.8M
YoY Change
Total Liabilities & Shareholders Equity $198.1M $223.0M
YoY Change -33.82% 8.07%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$26.26M -$33.19M
YoY Change 9.83% 39.52%
Depreciation, Depletion And Amortization $892.0K $900.0K
YoY Change 41.14% 0.0%
Cash From Operating Activities -$24.03M -$27.90M
YoY Change 30.96% 47.6%
INVESTING ACTIVITIES
Capital Expenditures $111.0K $470.0K
YoY Change -65.42% -257.72%
Acquisitions
YoY Change
Other Investing Activities $10.45M $41.00M
YoY Change -110.8% 215.38%
Cash From Investing Activities $10.33M $40.53M
YoY Change -110.65% 219.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 25.00K 170.0K
YoY Change -99.98% -95.83%
NET CHANGE
Cash From Operating Activities -24.03M -27.90M
Cash From Investing Activities 10.33M 40.53M
Cash From Financing Activities 25.00K 170.0K
Net Change In Cash -13.67M 12.80M
YoY Change 337.87% -702.35%
FREE CASH FLOW
Cash From Operating Activities -$24.03M -$27.90M
Capital Expenditures $111.0K $470.0K
Free Cash Flow -$24.14M -$28.37M
YoY Change 29.3% 52.49%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001817229
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39979
dei Entity Registrant Name
EntityRegistrantName
VOR BIOPHARMA INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-1591163
dei Entity Address Address Line1
EntityAddressAddressLine1
100 Cambridgepark Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 101
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02140
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
655-6580
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
VOR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
67805687
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
45026000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57706000
CY2023Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
115072000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
172539000
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3673000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4368000
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
667000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2337000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
164438000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
236950000
CY2023Q3 us-gaap Restricted Cash Equivalents Noncurrent
RestrictedCashEquivalentsNoncurrent
2413000
CY2022Q4 us-gaap Restricted Cash Equivalents Noncurrent
RestrictedCashEquivalentsNoncurrent
2413000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10824000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12634000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
41262000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
44444000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4086000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2925000
CY2023Q3 us-gaap Assets
Assets
223023000
CY2022Q4 us-gaap Assets
Assets
299366000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1309000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1772000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10274000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7889000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3743000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3272000
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
62000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
186000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
15388000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13119000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
32854000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
35640000
CY2023Q3 us-gaap Liabilities
Liabilities
48242000
CY2022Q4 us-gaap Liabilities
Liabilities
48759000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
67798343
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
66079597
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
67785469
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
65996138
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
7000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
488873000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
473587000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-280000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-770000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-313819000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-222217000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
174781000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
250607000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
223023000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
299366000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27606000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16875000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
73418000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
47488000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7710000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7226000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24494000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21205000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
35316000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
24101000
us-gaap Operating Expenses
OperatingExpenses
97912000
us-gaap Operating Expenses
OperatingExpenses
68693000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-35316000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-24101000
us-gaap Operating Income Loss
OperatingIncomeLoss
-97912000
us-gaap Operating Income Loss
OperatingIncomeLoss
-68693000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
2126000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
313000
us-gaap Investment Income Interest
InvestmentIncomeInterest
6310000
us-gaap Investment Income Interest
InvestmentIncomeInterest
509000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2126000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
313000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6310000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
509000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-33190000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-23788000
us-gaap Net Income Loss
NetIncomeLoss
-91602000
us-gaap Net Income Loss
NetIncomeLoss
-68184000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.63
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.63
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.37
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.37
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.81
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.81
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67607713
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67607713
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38009022
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38009022
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
66973771
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
66973771
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37582463
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37582463
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
156000
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
148000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
490000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1178000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
156000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
148000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
490000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1178000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33034000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23640000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-91112000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-69362000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
250607000
CY2023Q1 vor Stock Issued During Period Value Stock Options Vested Of Restricted Stock Units And Exercised
StockIssuedDuringPeriodValueStockOptionsVestedOfRestrictedStockUnitsAndExercised
-340000
CY2023Q1 vor Stock Issued During Period Value Issuance Of Common Stock From Open Market Sales Agreement
StockIssuedDuringPeriodValueIssuanceOfCommonStockFromOpenMarketSalesAgreement
3717000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4068000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
596000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-28433000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
230215000
CY2023Q2 vor Stock Issued During Period Value Vesting Of Restricted Stock Units Vesting And Exercise Of Stock Options And Employee Stock Purchase Plan
StockIssuedDuringPeriodValueVestingOfRestrictedStockUnitsVestingAndExerciseOfStockOptionsAndEmployeeStockPurchasePlan
-317000
CY2023Q2 vor Stock Issued During Period Value Issuance Of Common Stock From Open Market Sales Agreement
StockIssuedDuringPeriodValueIssuanceOfCommonStockFromOpenMarketSalesAgreement
555000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4238000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-262000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-29979000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
204450000
CY2023Q3 vor Stock Issued During Period Value Stock Options Vested Of Restricted Stock Units And Exercised
StockIssuedDuringPeriodValueStockOptionsVestedOfRestrictedStockUnitsAndExercised
-183000
CY2023Q3 vor Stock Issued During Period Value Issuance Of Common Stock From Open Market Sales Agreement
StockIssuedDuringPeriodValueIssuanceOfCommonStockFromOpenMarketSalesAgreement
386000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3162000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
156000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-33190000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
174781000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
216263000
CY2022Q1 vor Stock Issued During Period Value Stock Options Vested And Exercised
StockIssuedDuringPeriodValueStockOptionsVestedAndExercised
247000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1746000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1072000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-22737000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
194447000
CY2022Q2 vor Stock Issued During Period Value Stock Options Vested And Exercised
StockIssuedDuringPeriodValueStockOptionsVestedAndExercised
146000
CY2022Q2 vor Stock Issued During Period Value Issuance Of Common Stock From Open Market Sales Agreement
StockIssuedDuringPeriodValueIssuanceOfCommonStockFromOpenMarketSalesAgreement
553000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1741000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-254000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-21659000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
174974000
CY2022Q3 vor Stock Issued During Period Value Stock Options Vested And Exercised
StockIssuedDuringPeriodValueStockOptionsVestedAndExercised
279000
CY2022Q3 vor Stock Issued During Period Value Issuance Of Common Stock From Open Market Sales Agreement
StockIssuedDuringPeriodValueIssuanceOfCommonStockFromOpenMarketSalesAgreement
3792000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3329000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
148000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-23788000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
158734000
us-gaap Profit Loss
ProfitLoss
-91602000
us-gaap Profit Loss
ProfitLoss
-68184000
us-gaap Depreciation
Depreciation
2600000
us-gaap Depreciation
Depreciation
1893000
us-gaap Operating Lease Expense
OperatingLeaseExpense
3513000
us-gaap Operating Lease Expense
OperatingLeaseExpense
2451000
us-gaap Share Based Compensation
ShareBasedCompensation
11468000
us-gaap Share Based Compensation
ShareBasedCompensation
6816000
vor Interest Amortization Accretion On Marketable Securities
InterestAmortizationAccretionOnMarketableSecurities
3674000
vor Interest Amortization Accretion On Marketable Securities
InterestAmortizationAccretionOnMarketableSecurities
-163000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2646000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-9037000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2558000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-316000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2678000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-542000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1161000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
674000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-76266000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-66798000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
58369000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
5044000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
120000000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
16130000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
958000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8141000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
60673000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2945000
vor Payment Of Issuance Costs Related To Underwritten Public Offering And Concurrent Private Placement
PaymentOfIssuanceCostsRelatedToUnderwrittenPublicOfferingAndConcurrentPrivatePlacement
717000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4593000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4345000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1165000
vor Proceeds From Stock Option Exercises And The Issuance Of Shares Under Espp
ProceedsFromStockOptionExercisesAndTheIssuanceOfSharesUnderEspp
202000
vor Proceeds From Stock Option Exercises And The Issuance Of Shares Under Espp
ProceedsFromStockOptionExercisesAndTheIssuanceOfSharesUnderEspp
534000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2913000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4879000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-12680000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-58974000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
60119000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
122214000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
47439000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
63240000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
37000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
24207000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
63000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
56000
vor Financing Costs Associated With The Sale Of Common Stock Included In Accounts Payable And Accrued Expenses
FinancingCostsAssociatedWithTheSaleOfCommonStockIncludedInAccountsPayableAndAccruedExpenses
30000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
45026000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
60827000
CY2023Q3 us-gaap Restricted Cash Equivalents Noncurrent
RestrictedCashEquivalentsNoncurrent
2413000
CY2022Q3 us-gaap Restricted Cash Equivalents Noncurrent
RestrictedCashEquivalentsNoncurrent
2413000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
47439000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
63240000
us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Nature of the Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:5.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Vor Biopharma Inc. (the “Company”) is a clinical-stage cell and genome engineering company that combines a novel patient engineering approach with targeted therapies to provide a single company solution for patients suffering from hematological malignancies. The Company’s proprietary platform leverages its expertise in hematopoietic stem cell (“HSC”) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. The Company is headquartered in Cambridge, Massachusetts. The Company was incorporated on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 30, 2015</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:5.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to a number of risks common to development stage companies in the biotechnology industry, including, but not limited to, risks of failure of preclinical studies and clinical trials, dependence on key personnel, protection of proprietary technology, reliance on third party organizations, risks of obtaining regulatory approval for any product candidate that it may develop, development by competitors of technological innovations, compliance with government regulations, geopolitical tensions, adverse macroeconomic conditions and the need to obtain additional financing.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company anticipates that it will continue to incur significant operating losses for the next several years as it continues to develop its product candidates. The Company believes that its existing cash, cash equivalents and marketable securities at September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> will be sufficient to allow the Company to fund its current operations through at least a period of one year after the date the financial statements are issued.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2015-12-30
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:5.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the condensed consolidated financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies in developing the estimates and assumptions that are used in the preparation of the condensed consolidated financial statements. Management must apply significant judgment in this process. Management’s estimation process often may yield a range of potentially reasonable estimates and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: accrued expenses and research and development expenses.</span></p>
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
115352000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
281000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
115072000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
173309000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
770000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
172539000
vor Debt Securities Available For Sale Change In Present Values Expense Reversal
DebtSecuritiesAvailableForSaleChangeInPresentValuesExpenseReversal
0
vor Debt Securities Available For Sale Change In Present Values Expense Reversal
DebtSecuritiesAvailableForSaleChangeInPresentValuesExpenseReversal
0
vor Fair Value Assets Level1 To Level2 Transferred Amount
FairValueAssetsLevel1ToLevel2TransferredAmount
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
vor Fair Value Assets Level2 To Level1 Transferred Amount
FairValueAssetsLevel2ToLevel1TransferredAmount
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
18022000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
17244000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7198000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4610000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10824000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12634000
CY2023Q3 us-gaap Depreciation
Depreciation
900000
us-gaap Depreciation
Depreciation
2600000
CY2022Q3 us-gaap Depreciation
Depreciation
900000
us-gaap Depreciation
Depreciation
1900000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4269000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4408000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1559000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1701000
CY2023Q3 vor Clinical Expenses Current
ClinicalExpensesCurrent
1364000
CY2022Q4 vor Clinical Expenses Current
ClinicalExpensesCurrent
532000
CY2023Q3 vor Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
2353000
CY2022Q4 vor Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
569000
CY2023Q3 vor Manufacturing Expenses Current
ManufacturingExpensesCurrent
372000
CY2022Q4 vor Manufacturing Expenses Current
ManufacturingExpensesCurrent
328000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
357000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
351000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10274000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7889000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2247844
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2617264
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.65
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.08
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
17000000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
12874
CY2023Q3 vor Share Based Compensation Arrangement By Share Based Payment Award Option Unvested Exercised In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionUnvestedExercisedInPeriodWeightedAverageExercisePrice
1.36
CY2023Q3 vor Proceeds From Stock Unvested Option Exercised
ProceedsFromStockUnvestedOptionExercised
100000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3162000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3329000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11468000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6816000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1950000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1994000
us-gaap Operating Lease Cost
OperatingLeaseCost
5851000
us-gaap Operating Lease Cost
OperatingLeaseCost
4506000
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
663000
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
567000
us-gaap Variable Lease Cost
VariableLeaseCost
1921000
us-gaap Variable Lease Cost
VariableLeaseCost
1209000
CY2023Q3 us-gaap Lease Cost
LeaseCost
2613000
CY2022Q3 us-gaap Lease Cost
LeaseCost
2561000
us-gaap Lease Cost
LeaseCost
7772000
us-gaap Lease Cost
LeaseCost
5715000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
41262000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
44444000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3743000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3272000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
32854000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
35640000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
36597000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
38912000
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y10M24D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y8M12D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.082
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.082
us-gaap Operating Lease Payments
OperatingLeasePayments
4263000
us-gaap Operating Lease Payments
OperatingLeasePayments
10594000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
37000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
24207000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-33190000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-23788000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-91602000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-68184000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67607713
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67607713
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38009022
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38009022
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
66973771
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
66973771
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37582463
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37582463
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.63
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.63
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.37
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.37
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.81
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.81

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
vor-20230930_cal.xml Edgar Link unprocessable
vor-20230930_def.xml Edgar Link unprocessable
0000950170-23-060200-index-headers.html Edgar Link pending
0000950170-23-060200-index.html Edgar Link pending
0000950170-23-060200.txt Edgar Link pending
0000950170-23-060200-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vor-20230930.htm Edgar Link pending
vor-20230930.xsd Edgar Link pending
vor-ex31_1.htm Edgar Link pending
vor-ex31_2.htm Edgar Link pending
vor-ex32_1.htm Edgar Link pending
vor-20230930_lab.xml Edgar Link unprocessable
vor-20230930_pre.xml Edgar Link unprocessable
vor-20230930_htm.xml Edgar Link completed